Natural Product (NP) Details
| General Information of the NP (ID: NP4862) | |||||
|---|---|---|---|---|---|
| Name |
Biochanin A
|
||||
| Synonyms |
Biochanin; 4'-Methylgenistein; 5,7-Dihydroxy-4'-methoxyisoflavone; 5,7-Dihydroxy-3-(4-methoxyphenyl)-4H-chromen-4-one; Genistein 4-methyl ether; 5,7-Dihydrox -4'-methoxyisoflavone; Biochanine A; 4H-1-Benzopyran-4-one, 5,7-dihydroxy-3-(4-methoxyphenyl)-; olmelin; Pratensol; NSC 123538; Biochanin-A; 5,7-dihydroxy-3-(4-methoxyphenyl)chromen-4-one; 4-Methylgenistein; C16H12O5; UNII-U13J6U390T; CCRIS 5449; 5,7-Dihydroxy-3-p-methoxyphenyl-4H-chromen-4-one; EINECS 207-744-7; NSC123538; Genistein 4'-methyl ether; 4'-methylgenistein; BIOCHANIN; 491-80-5
Click to Show/Hide
|
||||
| Species Origin | Cicer arietinum ... | Click to Show/Hide | |||
| Cicer arietinum | |||||
| Glycine max | |||||
| Trifolium pratense | |||||
| Cotoneaster pannosus | |||||
| Myristica malabarica | |||||
| Dalbergia volubilis | |||||
| Disease | Idiopathic pulmonary fibrosis [ICD-11: CB03] | Investigative | [1] | ||
| Structure |
|
Click to Download Mol2D MOL |
|||
| ADMET Property |
Absporption
Caco-2 Permeability
-5.009
MDCK Permeability
-4.829
PAMPA
- -
HIA
- - -
Distribution
VDss
-0.081
PPB
97.2%
BBB
- - -
Metabolism
CYP1A2 inhibitor
+++
CYP1A2 substrate
+++
CYP2C19 inhibitor
+++
CYP2C19 substrate
- - -
CYP2C9 inhibitor
- -
CYP2C9 substrate
+++
CYP2D6 inhibitor
+++
CYP2D6 substrate
+++
CYP3A4 inhibitor
+++
CYP3A4 substrate
- - -
CYP2B6 inhibitor
+++
CYP2B6 substrate
- - -
CYP2C8 inhibitor
+++
HLM Stability
-
Excretion
CLplasma
5.446
T1/2
0.858
Toxicity
DILI
++
Rat Oral Acute Toxicity
+
FDAMDD
++
Respiratory
++
Human Hepatotoxicity
-
Ototoxicity
- -
Drug-induced Nephrotoxicity
- -
Drug-induced Neurotoxicity
-
Hematotoxicity
- -
Genotoxicity
+++
Tips: 1. For the classification endpoints, the prediction probability values are transformed into six symbols: 0-0.1 (- - -), 0.1-0.3 (- -), 0.3-0.5 (-), 0.5-0.7 (+), 0.7-0.9 (++), and 0.9-1.0 (+++).
2. Additionally, the corresponding relationships of the three labels are as follows: excellent; medium; poor.
Click to Show/Hide
|
||||
| Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | |||||
| Formula |
C16H12O5
|
||||
| PubChem CID | |||||
| Canonical SMILES |
COC1=CC=C(C=C1)C2=COC3=CC(=CC(=C3C2=O)O)O
|
||||
| InChI |
1S/C16H12O5/c1-20-11-4-2-9(3-5-11)12-8-21-14-7-10(17)6-13(18)15(14)16(12)19/h2-8,17-18H,1H3
|
||||
| InChIKey |
WUADCCWRTIWANL-UHFFFAOYSA-N
|
||||
| CAS Number |
CAS 491-80-5
|
||||
| Herb ID | |||||
| SymMap ID | |||||
| TTD Drug ID | |||||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. A List of Drug(s) Whose Efficacy can be Enhanced by This NP | ||||||
| Temozolomide | Brain cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
| Augmenting Drug Sensitivity | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [2] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Down-regulation | Phosphorylation | AKT1 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | EGFR | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Phosphorylation | ERK1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | MYC | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Phosphorylation | TP53 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | U-87MG ATCC | CVCL_0022 | Glioblastoma | Homo sapiens | ||
| T98G | CVCL_0556 | Glioblastoma | Homo sapiens | |||
| Experimental
Result(s) |
Biochanin A significantly enhanced the anticancer efficacy of temozolomide in GBM cells. | |||||
| Target and Pathway | ||||
|---|---|---|---|---|
| Target(s) | Aromatase (CYP19A1) | Molecule Info | [3] | |
| Estrogen-related receptor (ESRR) | Molecule Info | [4] | ||
| Fatty acid synthase (FASN) | Molecule Info | [5] | ||
| Plasmodium Fatty acid synthesis protein (Malaria FabZ) | Molecule Info | [5] | ||
| BioCyc | Fatty acid biosynthesis initiation | Click to Show/Hide | ||
| 2 | Fatty acid elongation -- saturated | |||
| 3 | Palmitate biosynthesis | |||
| 4 | Superpathway of steroid hormone biosynthesis | |||
| 5 | Estradiol biosynthesis II | |||
| 6 | Estradiol biosynthesis I | |||
| KEGG Pathway | Fatty acid biosynthesis | Click to Show/Hide | ||
| 2 | Metabolic pathways | |||
| 3 | Fatty acid metabolism | |||
| 4 | AMPK signaling pathway | |||
| 5 | Insulin signaling pathway | |||
| 6 | Steroid hormone biosynthesis | |||
| 7 | Ovarian steroidogenesis | |||
| 8 | Fatty acid biosynthesis | |||
| 9 | Biotin metabolism | |||
| 10 | Metabolic pathways | |||
| 11 | Fatty acid metabolism | |||
| NetPath Pathway | FSH Signaling Pathway | Click to Show/Hide | ||
| Panther Pathway | Androgen/estrogene/progesterone biosynthesis | Click to Show/Hide | ||
| Pathwhiz Pathway | Fatty Acid Biosynthesis | Click to Show/Hide | ||
| 2 | Androgen and Estrogen Metabolism | |||
| Pathway Interaction Database | p73 transcription factor network | Click to Show/Hide | ||
| 2 | Validated transcriptional targets of deltaNp63 isoforms | |||
| Reactome | ChREBP activates metabolic gene expression | Click to Show/Hide | ||
| 2 | Activation of gene expression by SREBF (SREBP) | |||
| 3 | Fatty Acyl-CoA Biosynthesis | |||
| 4 | Endogenous sterols | |||
| WikiPathways | Fatty Acid Biosynthesis | Click to Show/Hide | ||
| 2 | Nuclear Receptors Meta-Pathway | |||
| 3 | Liver X Receptor Pathway | |||
| 4 | Activation of Gene Expression by SREBP (SREBF) | |||
| 5 | SREBF and miR33 in cholesterol and lipid homeostasis | |||
| 6 | SREBP signalling | |||
| 7 | Metabolism of water-soluble vitamins and cofactors | |||
| 8 | Integration of energy metabolism | |||
| 9 | Fatty acid, triacylglycerol, and ketone body metabolism | |||
| 10 | AMPK Signaling | |||
| 11 | Metapathway biotransformation | |||
| 12 | Tryptophan metabolism | |||
| 13 | Oxidation by Cytochrome P450 | |||
| 14 | Ovarian Infertility Genes | |||
| 15 | Metabolism of steroid hormones and vitamin D | |||
| 16 | FSH signaling pathway | |||
| 17 | Integrated Breast Cancer Pathway | |||
| 18 | Phase 1 - Functionalization of compounds | |||
